Remote ALS Launch & Access Strategist

Otsuka America Pharmaceutical Inc.; Providence (RI); Remote; USD 158,000 - 252,000; Full time

Benefits offered by this job

Medical benefits

Dental benefits

Vision coverage

401(k) match

Paid time off

Job summary

Otsuka America Pharmaceutical Inc. seeks a Strategic Account Liaison to support the launch and growth of its rare neurology portfolio, focusing on ALS centers, providers, and key stakeholders.

The role requires communicating complex clinical data and navigating access and patient support programs to optimize care. The SAL will lead regional strategies, engage with KOLs, and coordinate with Market Access and Patient Support to reduce barriers to therapy while evolving with new programs in rare

Qualifications

• Understand complex disease states and articulate clinical data clearly.
• Educate on screening and diagnostic pathways and treatment options.
• Build and maintain relationships with HCPs and KOLs.
• Explain access and patient support programs to ensure prescribing flow.

Responsibilities

• Engage with ALS Centers of Excellence and healthcare providers to support patient care.
• Educate on disease state awareness and screening pathways.
• Develop account plans using data insights to drive regional strategy.
• Navigate site-of-care logistics, patient onboarding, and therapy initiation barriers.
• Collaborate with cross-functional teams to meet program objectives.

Skills

Clinical acumen

Relationship building

Communication

Cross-functional collaboration

Medical knowledge

Education

Bachelor's Degree

Job description

Otsuka America Pharmaceutical Inc. seeks a Strategic Account Liaison to support the launch and growth of its rare neurology portfolio, focusing on ALS centers, providers, and key stakeholders.

The role requires communicating complex clinical data and navigating access and patient support programs to optimize care. The SAL will lead regional strategies, engage with KOLs, and coordinate with Market Access and Patient Support to reduce barriers to therapy while evolving with new programs in rare